Heart valve allografts
This article was originally published in The Gray Sheet
Executive Summary
Washington Legal Foundation files suit in the U.S. district court for the District of Columbia on March 4, seeking to enjoin FDA from enforcing its policy of requiring premarket approval applications for human heart valve allografts. WLF argues that the allografts do not fall within the definition of medical devices in the 1976 device law. In May, the group petitioned FDA to withdraw its June 1991 final rule requiring PMAs for the valves. That petition was denied on Feb. 8.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.